XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
तुलना करने के लिए मीट्रिक्स | XTLB | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधXTLBपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −11.5x | −2.0x | −0.5x | |
PEG अनुपात | −1.39 | −0.02 | 0.00 | |
क़ीमत/बुक | 2.2x | 1.8x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 26.2x | 7.2x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 757.1% | 47.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 21.6% | 6.9% | अनलॉक करें |